BFM
ELVN icon

Boothbay Fund Management’s Enliven Therapeutics ELVN Stock Holding History

Boothbay Fund Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-76,975
Closed -$1.51M – 1541
2025
Q1 		$1.51M Sell
76,975
-27,915
-27% -$601K 0.04% 501
2024
Q4 		$2.36M Sell
104,890
-27,943
-21% -$724K 0.06% 403
2024
Q3 		$3.39M Sell
132,833
-23,129
-15% -$536K 0.08% 355
2024
Q2 		$3.64M Buy
+155,962
New +$3.28M 0.09% 316

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boothbay Fund Management's ELVN Position: Q2 2025 in Review

Boothbay Fund Management sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 76,975 shares — an estimated $1.51M sold.

Boothbay Fund Management first reported a position in ELVN in Q2 2024 and held it in 4 quarters. The position peaked at $3.64M in Q2 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Boothbay Fund Management reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 76,975 Enliven Therapeutics shares in Q2 2025, an estimated $1.51M.
  • Boothbay Fund Management first reported a position in Enliven Therapeutics in Q2 2024 and held it in 4 quarters.
  • Boothbay Fund Management's Enliven Therapeutics position peaked at $3.64M in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.